Pre-made Avizakimab benchmark antibody ( Whole mAb, anti-IL21 therapeutic antibody, Anti-CVID11/IL-21/Za11 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Avizakimab biosimilar, Whole mAb, Anti-IL21 Antibody: Anti-CVID11/IL-21/Za11 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Avizakimab (formerly BOS 161721) is a fully human anti-interleukin 21 monoclonal antibody, being developed by Boston Pharmaceuticals, for treatment of autoimmune disorders including systemic lupus erythematosus.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-041-1mg	1mg	3090	Inquiry	Inquiry

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Avizakimab biosimilar, Whole mAb, Anti-IL21 Antibody: Anti-CVID11/IL-21/Za11 therapeutic antibody
INN Name	Avizakimab
Target	IL21
Format	Whole mAb
Derivation
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-I/II
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2019
Year Recommended	2020
Companies	MedImmune;Boston Pharmaceuticals
Conditions Approved	na
Conditions Active	Systemic lupus erythematosus
Conditions Discontinued	Autoimmune disorders
Development Tech	na